Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Table 2 Change in concentrations of serum lipids and apoproteins

Varuables	Before	4 wk	8 wk	12 wk
TC (mg/dL)	206.3 ± 26.5	186.3 ± 22.9	189.9 ± 27.7a	192.1 ± 30.1
TG (mg/dL)	126.0 ± 50.1	119.5 ± 76.2	102.8 ± 52.3	103.6 ± 53.0
HDL-C (mg/dL)	63.6 ± 11.3	63.8 ± 14.0	68.8 ± 12.6	69.3 ± 13.1
LDL-C (mg/dL)	115.7 ± 22.1	99.3 ± 29.3	105.6 ± 28.0	105.2 ± 25.1
Apo A-I (mg/dL)	159.0 ± 17.9	154.7 ± 19.4	158.3 ± 17.9	172.1 ± 24.3
Apo A-II (mg/dL)	31.6 ± 6.5	39.5 ± 7.0a	40.7 ± 4.6a	44.1 ± 4.9a
Apo B (mg/dL)	95.1 ± 22.9	84.1 ± 31.4	81.0 ± 26.5	84.1 ± 23.1
Apo C- II (mg/dL)	3.9 ± 1.7	4.6 ± 2.0a	4.2 ± 1.6	4.5 ± 1.5a
Apo C-III (mg/dL)	9.7 ± 3.8	9.5 ± 4.2	8.9 ± 2.9	9.8 ± 3.6
Apo E (mg/dL)	4.3 ± 1.0	4.3 ± 0.8	4.4 ± 0.8	4.6 ± 0.9

TC: total cholesterol, TG: triglyceride, HDL-C: HDL-cholesterol, LDL-C: LDL-cholesterol, Apo: apoprotein.

^aP < 0.05 (baseline-matched t-test) vs the serum concentrations prior to the treatment.